Immunotherapy

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.

What is Immunotherapy?

Immunotherapy is a treatment that is designed to harness the ability of the body’s immune system to combat infection or disease.

Immunotherapy: Past, Present and Future

Activation Immunotherapies

Suppression Immunotherapies

Neoantigens' Role in Immunotherapy

Immunotherapy: The Future of Lung Cancer Treatment?

Adoptive T Cell Therapy Methodology

Adoptive T Cell Therapy Applications

Immunotherapy and Helminthic Therapy

Latest Immunotherapy News and Research

Rising colorectal cancer rates prompt earlier routine screening recommendations

Forty-five is the new 60 – at least when it comes to colonoscopies. That may not be the party you look forward to, but it could save your life. According to the Cancer Research Institute, 1 in 5 colorectal cancers are diagnosed in patients under age 55, making what was once thought of as an older person's disease one of the fastest-growing cancers in young people.

5 Nov 2026

Organoid coculture platforms enhance preclinical prediction of drug efficacy

Three‐dimensional cancer organoids cultured in vitro closely recapitulate the phenotypic and genetic features of parental tumor tissues, making them powerful tools for cancer research, drug screening, and personalized medicine.

5 Nov 2026

Three-drug combination remodels immune environment in gastric cancer

A triplet combination therapy can remodel the tumor microenvironment in patients with advanced gastric cancer and shows a promising safety profile, according to results from a new phase 2 clinical trial.

5 Nov 2026

Supervised food challenges clear many infants of suspected peanut allergy

A world-first national program has discovered more than a third of babies thought to have a peanut allergy could safely have the diagnosis removed. And the findings are changing how Australia's healthcare system approaches infant food allergies.

4 Nov 2026

AlphaFold3 reveals molecular interactions driving T cell recognition

Researchers at the Translational Genomics Research Institute (TGen), part of City of Hope, have developed a new approach using the artificial intelligence platform AlphaFold3 to predict whether a T cell receptor will recognize a specific antigen based solely on its genetic sequence.

3 Nov 2026

Engineered beneficial bacteria reduce bloodstream infections after stem cell transplants

Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, and collaborators have pioneered a new approach to preventing dangerous bloodstream infections in patients receiving donor stem cell transplants for blood cancers.

3 Nov 2026

Immunotherapy reshapes immune cell interactions in melanoma-affected lymph nodes

A new study from Mayo Clinic suggests checkpoint immunotherapy may reshape the immune environment within lymph nodes after melanoma has spread to them.

30 Oct 2026

Hyperactive cancer-promoting proteins help tumor cells evade immune attack

The immune system may recognize a cancer cell and still fail to destroy it. Researchers at Hiroshima University and their international collaborators found that hyperactive YAP and TAZ (YAP/TAZ), two cancer-promoting proteins, were associated with genomic instability that may make cancer cells more recognizable to the immune system, while also increasing PD-L2, which helps the cells suppress T-cell attack.

30 Oct 2026

Targeting specific enzyme reverses radiation-induced immune suppression in cancer

Researchers at the University of Chicago identified a mechanism to make immune cells reprogrammed by radiation therapy attack tumors rather than protect them.

30 Oct 2026

Researchers find simple way to boost engineered T-cell therapies

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a promising new strategy to make cancer-fighting immune cells stronger and potentially longer-lasting, a discovery that could help improve the effectiveness of immunotherapies that use a patient's own immune cells to attack cancer.

29 Oct 2026

Mutated neutrophils may trigger immune attacks in lupus

Scientists at La Jolla Institute for Immunology (LJI) and the University of Washington (UW) have discovered that patients with lupus have unusual mutations that may turn their bodies into battlegrounds.

28 Oct 2026

Dual-targeting antibody successfully tackles multiple tumor types in mice

A novel antibody therapy empowers the immune system's tumor-fighting capabilities in mice by targeting immune-suppressing T cells with greater precision than previous approaches, according to new work.

28 Oct 2026

Targeted drug combination extends survival in advanced kidney cancer

Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer.

28 Oct 2026

Lab-on-a-chip technology helps predict childhood leukemia treatment responses

More than 120,000 people in the U.S. are living with acute lymphoblastic leukemia (ALL), and 6,000 new cases are diagnosed each year. Of those, more than 3,500 will be in children.

27 Oct 2026

Patients with a form of advanced lung cancer lived 56 percent longer without their disease progressing after receiving radiotherapy in addition to standard treatment

Patients with an advanced form of lung cancer lived 56 percent longer without their disease progressing when radiotherapy was added to the standard of care whole-body therapy, including chemotherapy and/or immunotherapy, according to initial results from a clinical trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.

27 Oct 2026

Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer

In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter, randomized DeLLphi-305 study, which was presented by Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, during the Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, on Oct. 24.

26 Oct 2026

New drug effectively decreases recurrence of and death from endometrial cancer

A new drug is effective at decreasing recurrence of and death from endometrial cancer, a landmark international study shows.

26 Oct 2026

Phase 3 EMT2 trial demonstrates survival benefit for high-dose EPA

Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase 3 EMT2 trial presented at the ESMO Congress 2026.

26 Oct 2026

Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy

Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.

24 Oct 2026

Drug combination delivers promising survival gains in advanced endometrial cancer

An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.

24 Oct 2026